Ananda Developments - Presenting at Aquis Showcase
Announcement provided by
Ananda Developments Plc · ANA04/11/2024 07:00
4 November 2024
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Presentation at Aquis Showcase
Ananda Developments plc (AQSE: ANA), a Company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is pleased to announce that it will be presenting at the Aquis Stock Exchange Showcase on Tuesday 12th November in
Finance Director Jeremy Sturgess-Smith will deliver an eight-minute pitch, followed by a rapid-fire Q&A session to a live investor audience.
The event will provide an opportunity to hear directly from the management team on the Company's pharmaceutical product development plans and to connect with them in person.
Investors interested in attending can register here with the code 'AQ20'.
-Ends-
To stay abreast of the latest developments at Ananda, follow our social media channels at:
· Investor Hub: investors.anandadevelopments.com
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC |
+44 (0)7463 686 497 |
|
ir@anandadevelopments.com |
Chief Executive Officer |
|
Melissa Sturgess |
|
|
|
Finance Director |
|
Jeremy Sturgess-Smith |
|
|
|
SP ANGEL CORPORATE FINANCE LLP |
+44 (0)20 3470 0470 |
|
|
Corporate Finance |
|
Richard Morrison |
|
|
|
|
|
Corporate Broking |
|
Abigail Wayne |
|
Rob Rees
|
|
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 ananda@yellowjerseypr.com |
About Ananda Developments
Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions.
For more information, please visit: https://anandadevelopments.com
https://investors.anandadevelopments.com/link/5PmQqP
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.